Search Results - B. Yа. Alekseev

Refine Results
  1. 1
    Kidney Injury Molecule 1 (KIM-1): a Multifunctional Glycoprotein and Biological Marker (Review)

    Kidney Injury Molecule 1 (KIM-1): a Multifunctional Glycoprotein and Biological Marker (Review) by Т. А. Кармакова, Н. С. Сергеева, K. Yu. Kanukoev, B. Yа. Alekseev, А. Д. Каприн

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2

    RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RE... by Alain Ravaud, Carlos H. Barrios, Oezlem Anak, Diana Pelov, A.-L. Louveau, B. Yа. Alekseev, Tattersall Mh, Sanjiv S. Agarwala, Sıddika Songül Yalçın, Bohuslav Melichar

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines

    Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines by A. V. Razumovskaya, M. O. Silkina, А. А. Полозников, Timur Kulagin, M. P. Raigorodskaya, N. A. Gorban, Anna V. Kudryavtseva, Maria Fedorova, B. Yа. Alekseev, Alexander Tonevitsky, С. В. Никулин

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES... by Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, B. Yа. Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, Bertrand Tombal, Robert Morlock, Cristina Ivanescu, Krishnan Ramaswamy, Fred Saad, Andrew J. Armstrong

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways

    Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways by Ksenia Lezhnina, Olga Kovalchuk, Alex Zhavoronkov, Mikhail Korzinkin, Anastasia A. Zabolotneva, Peter Shegay, Д Г Соков, Нуршат Гайфуллин, И. Г. Русаков, Alexander Aliper, S. A. Roumiantsev, B. Yа. Alekseev, Nikolay Borisov, Anton Buzdin

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Important molecular genetic markers of colorectal cancer

    Important molecular genetic markers of colorectal cancer by Anna V. Kudryavtseva, Anastasiya V. Lipatova, Andrew R. Zaretsky, Alexey Moskalev, Maria Fedorova, Anastasiya S. Rasskazova, Galina A. Shibukhova, Anastasiya V. Snezhkina, А. Д. Каприн, B. Yа. Alekseev, Alexey A. Dmitriev, George S. Krasnov

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Mitochondrial dysfunction and oxidative stress in aging and cancer

    Mitochondrial dysfunction and oxidative stress in aging and cancer by Anna V. Kudryavtseva, George S. Krasnov, Alexey A. Dmitriev, B. Yа. Alekseev, Olga Kardymon, А. Ф. Садритдинова, Maria Fedorova, A. V. Pokrovsky, Nataliya V. Melnikova, А. Д. Каприн, Alexey Moskalev, Anastasiya V. Snezhkina

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer by Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R. Smith

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

    Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a rand... by Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N.

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

    RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma by Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev, M.-H. Tay, Sanjiv S. Agarwala, Şuayib Yalçın, C.-C. Lin, Laslo Roman, М. I. Shkolnik, Oezlem Anak, Svetozar Gogov, Diana Pelov, A.-L. Louveau, Bohuslav Melichar

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

    LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER by Neal D. Shore, Matthew R. Smith, Tuevo L.J. Tammela, Albertas Ulys, Eglis Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, I. Kuss, Marie A. Le Berre, Amir Snapir, Toni Sarapohja, Karim Fizazi

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide by Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie‐Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

    223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate can... by Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, M-A. Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c‐Myc and C/EBP<i>β</i> rather than Enterotoxigenic <i>Bacteroides fragilis</i> Infection

    The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c‐Myc and C/EBP<i>β</i> rather than Enterotoxigenic <i>Bacteroides fragilis</i>... by Anastasiya V. Snezhkina, George S. Krasnov, Anastasiya V. Lipatova, А. Ф. Садритдинова, Olga Kardymon, Maria Fedorova, Nataliya V. Melnikova, О. А. Степанов, Andrew R. Zaretsky, А. Д. Каприн, B. Yа. Alekseev, Alexey A. Dmitriev, Anna V. Kudryavtseva

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

    Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer by Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N.

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer by Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, B. Yа. Alekseev, Taro Iguchi, Neal D. Shore, Brad Rosbrook, Jennifer Sugg, Benoît Baron, Lucy Chen, Arnulf Stenzl

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

    Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial by Jun Pang, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie A. Le Berre, Amir Snapir, Toni Sarapohja, Karim Fizazi

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

    LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy... by Andrew J. Armstrong, Taro Iguchi, Arun Azad, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, B. Yа. Alekseev, Neal D. Shore, Daniel P. Petrylak, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma

    Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma by Alexey A. Dmitriev, E. E. Rudenko, Anna V. Kudryavtseva, George S. Krasnov, V. V. Gordiyuk, Nataliya V. Melnikova, E. O. Stakhovsky, О. Кононенко, Larissa Pavlova, Tatiana T. Kondratieva, B. Yа. Alekseev, Э. А. Брага, В. Н. Сенченко, В. И. Кашуба

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial by Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Carsten Goessl, Joseph E. Burgents, Robert Kozarski, Darren Hodgson, Maria Learoyd, Fred Saad

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: